Navigation Links
Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
Date:10/19/2009

SAN DIEGO, Calif., Oct. 19, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation. Obesity 2009 is one of the largest scientific conferences in the field of obesity.

Amylin will also present new scientific findings from preclinical studies related to its clinical-stage obesity programs for pramlintide/metreleptin and davalintide, an optimized amylin analog. These findings include new insights into the synergistic weight loss observed with various dual-hormone combination regimens. Additionally, Amylin will present at the meeting's pre-conference session focused on obesity pharmacotherapy.

"The discovery of leptin and its role, along with other endocrine signals, in regulating body weight through a neurohormonal feedback system marked the beginning of a new era of obesity research," said Christian Weyer, M.D., vice president, Medical Development at Amylin Pharmaceuticals. "Amylin's unique approach to obesity drug development aims to translate this evolving science into innovative new treatment options and builds on over 20 years of experience in peptide-protein therapeutics."

Key Amylin Activities at Obesity 2009:

Saturday, October 24

  • Pharmacotherapy Update invited presentation: Christian Weyer, M.D., vice president, Medical Development will present at this pre-conference session scheduled from 1:00 - 3:45 p.m. ET.

Sunday, October 25

  • Poster 190-P: "Central Mechanisms Underlying Am
    '/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... that may indicate a patient,s risk of developing a ... therapies or chemicals is one of several medical discoveries ... DGX ) will present during the 51st American ... 5-8, 2009, in New Orleans, LA. ,, In ...
(Date:12/3/2009)... 3 Ted Karkus, Chairman and CEO of The ... announced today that the Company has completed its evaluation ... products and has concluded that it is in its ... marketplace, which may include but are not limited to ...
(Date:12/3/2009)... leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities ... America in Chicago. The Connect.PACS(TM) ... its kind, is the latest release in the ... ,, (Photo: http://www.newscom.com/cgi-bin/prnh/20091203/NE20631 ...
Breaking Medicine Technology:Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3ALung Secures 242 5 Million 5245 1ALung Secures 242 5 Million 5245 2Ethnic background may be associated with diabetes risk 58933 1Ethnic background may be associated with diabetes risk 58933 2Jerome Bettis Endorses Chews 4 Health Dietary Supplements 58932 1Jerome Bettis Endorses Chews 4 Health Dietary Supplements 58932 2Jerome Bettis Endorses Chews 4 Health Dietary Supplements 58932 3
... Dec. 18 Alseres,Pharmaceuticals, Inc., (Nasdaq: ALSE ... subject in the initial stage of the ALTROPANE(R) ... clinical trial program. This,subject was enrolled at the ... of Principal Investigator Dr. Ray L. Watts, MD,Professor ...
... Curemark,s Board of Directors,announced today that Steven M. Schwarz, ... senior scientist and will serve on the company,s Scientific,Advisory ... of,Pediatrics at The Long Island College Hospital and Professor ... Science Center at Brooklyn., "Dr. Schwartz is one ...
Other Medicine Technology:Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program 2Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program 3Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program 4Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program 5Curemark Appoints Preeminent Pediatrics Gastroenterologist 2
(Date:12/6/2009)... LLP says dangerous substances such as asbestos have been found in ... ... NY (PRWEB) December 6, 2009 -- As parents shop for children,s ... of recalls due to lead paint or asbestos contamination, says a ... hospital emergency rooms each year due to toy-related injuries,” says Joseph ...
(Date:12/5/2009)... --In Youngest Babies, This Type of Blood Cancer Is ... Dec. 5 Pediatric oncologists have identified specific genes, ... drive an often-fatal form of leukemia in infants. By ... better predict which infants may benefit from particular treatments. ...
(Date:12/5/2009)... innovative new international private medical insurance plan which follows the acclaimed ... the flexibility to add or remove a wide range of options ... tailor their benefits to complement those already offered in their country ... ...
(Date:12/4/2009)... Thousands of KPMG LLP employees came together in more ... service event which combines the audit, tax and advisory firm,s ... service day reflects our firm,s long history of volunteerism. Instead ... caring to brighten the holidays for some children," said Tim ...
(Date:12/4/2009)... KANSAS CITY, Mo., Dec. 4 The large, two-day free ... (NAFC) in Kansas City on Wednesday and Thursday is not ... uninsured and has not seen a doctor recently. All participants ... ,, "Many people who attended the three previous large free ...
Breaking Medicine News(10 mins):Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:Free Health Clinic Event Is Not Just for the Sick 2
... seafood per week during pregnancy was associated with higher ... a new study. ,The research is significant ... pregnancy, which state women should not eat more than ... to trace amounts of pollutants in the fish, like ...
... be able to be filtered from human blood saving ... world-first innovation by Queensland University// of Technology scientists. ... membranes for nanofiltration, which are so advanced they have ... blood. ,Associate Professor Huaiyong Zhu, from ...
... $10 million to the Global Fund in the fight ... ,The President made the announcement in a goodwill ... of the Global Fund Africa, set up to fight ... Monday February 12. ,President Obasanjo said, "If ...
... project on magnetic resonance imaging (MRI) could revolutionize ... diagnosing cancer and// other illnesses. ,Naresh ... Florida State University (FSU) and a graduate of ... the University of Colorado and the National Institute ...
... integrated private healthcare provider,// has joined hands with Hayel Saeed ... healthcare system to Yemen. ,The two groups ... in Taiz, Yemen, said a statement by Apollo Group here. ... and also the honorary deputy governor of Taiz State in ...
... smoking are significantly more likely to remain// smoke-free, says ... smokers with acute cardiovascular disease are more likely to ... program. ,“Smoking is the greatest risk factor ... Mohiuddin, MD, FCCP, Creighton University Cardiac Center, Omaha, NE, ...
Other Medicine News:Health News:Fish Intake Linked to Higher IQ in Offspring 2Health News:QUT Scientists on the Way to Sifting Out a Cure for HIV 2Health News:Indian American's Research Could Lead to Improved MRI 2Health News:Intense Cessation Treatment Proves Successful in High-Risk Smokers 2
... tracking and billing. This ... Handheld application, a complete ... CPT™ and ICD-9-CM codes ... Designed for any medical ...
Archimedes is an innovative specialty calculator. Forget having to remember complicated formulas, just enter the values and out come the results....
... provides safe, effective, current, and ... a quickly accessible format. The ... the latest drugs approved by ... implications are highlighted throughout. This ...
Alphabetically organized monographs on more than 1,000 generic and 3,000 trade name drugs....
Medicine Products: